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BurrowingType I interferons (IFN-I) are expressed in the brain during many inﬂammatory and neurodegenerative
conditions and have multiple effects on CNS function. IFN-I is readily induced in the brain by systemic
administration of the viral mimetic, poly I:C (synthetic double-stranded RNA). We hypothesised that
IFN-I contributes to systemically administered poly I:C-induced sickness behaviour, metabolic and neu-
roinﬂammatory changes. IFN-I receptor 1 deﬁcient mice (IFNAR1/) displayed signiﬁcantly attenuated
poly I:C-induced hypothermia, hypoactivity and weight loss compared to WT C57BL/6 mice. This amelio-
ration of sickness was associated with equivalent IL-1b and TNF-a responses but much reduced IL-6
responses in plasma, hypothalamus and hippocampus of IFNAR1/ mice. IFN-b injection induced trivial
IL-6 production and limited behavioural change and the poly I:C-induced IFN-b response did not preceed,
and would not appear to mediate, IL-6 induction. Rather, IFNAR1/ mice lack basal IFN-I activity, have
lower STAT1 levels and show signiﬁcantly lower levels of several inﬂammatory transcripts, including
stat1. Basal IFN-I activity appears to play a facilitatory role in the full expression of the IL-6 response
and activation of the tryptophan-kynurenine metabolism pathway. The deﬁcient IL-6 response in
IFNAR1/ mice partially explains the observed incomplete sickness behaviour response.
Reconstitution of circulating IL-6 revealed that the role of IFNAR in burrowing activity is mediated via
IL-6, while IFN-I and IL-6 have additive effects on hypoactivity, but the role of IFN-I in anorexia is inde-
pendent of IL-6. Hence, we have demonstrated both interdependent and independent roles for IFN-I and
IL-6 in systemic inﬂammation-induced changes in brain function.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Type one interferons, IFN-a and IFN-b (IFN-I) are produced by
most cell types in response to viral and bacterial pathogens
(Colonna et al., 2002) and have multiple roles in antiviral defense,
cell growth regulation and immune activation. IFN-I signals
through the heterodimeric receptor composed of IFNAR1 and
IFNAR2, inducing cross phosphorylation of Tyk2 and Jak1, which
leads to tyrosine phosphorylation and activation of signal trans-
ducers and activators of transcription (STATs) STAT1 and STAT2.
These, in turn, form transcriptional activator complexes througha series of signalling cascades leading to the activation of transcrip-
tion factors, translocation to the nucleus and binding of the inter-
feron-stimulated response element (ISRE), to induce transcription
of >500 IFN stimulated genes (ISGs) (Taniguchi et al., 2001).
It has emerged that IFN-I and downstream genes are readily
induced in the brain (Cunningham et al., 2007; Wang et al.,
2008) and have multiple effects on brain function and pathology
(Owens et al., 2014). While recombinant IFN-b is a ﬁrst line treat-
ment for relapsing-remitting Multiple Sclerosis, IFN-a, when used
to treat cancer and hepatitis, has been shown to induce sickness
behaviour, depression, anxiety, cognitive impairment and even
delirium (Capuron and Miller, 2004; Schaefer et al., 2002; Raison
et al., 2005). Chronic overexpression of IFN-a produces CNS pathol-
ogy (Campbell et al., 1999) and intracerebroventricular adminis-
tration of blocking antibodies against IFNAR protected against
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(Baruch et al., 2014). Acute changes in IFN-I also impact on temper-
ature, sleep (Krueger et al., 1988), circadian rhythm (Koyanagi and
Ohdo, 2002) and feeding behaviour (Plata-Salaman, 1992). IFN-b
has been shown to increase interictal-like spontaneous activity in
hippocampal neurons (Costello and Lynch, 2013) and to downreg-
ulate the brain-derived neurotrophic factor (BDNF) receptor, TrkB
(Dedoni et al., 2012).
Poly I:C is a synthetic double stranded RNA, commonly used as
a viral mimetic, that is recognised by TLR3 receptors on endosomal
membranes and by the cytoplasmic proteins RIG I and MDA5
(Alexopoulou et al., 2001; Yoneyama et al., 2004; Andrejeva
et al., 2004; Kato et al., 2005). Systemically administered poly
I:C, induces, in mice and rats, the classical features of sickness
behaviour (Hart, 1988), including fever/hypothermia, malaise,
hypoactivity, anhedonia, sleep/wake cycle disruption and anorexia
(Fortier et al., 2004; Cunningham et al., 2007; Majde, 2000; Traynor
et al., 2006). There is also evidence for effects of systemic (Kranjac
et al., 2012; Dilger and Johnson, 2010) or intracerebroventricular
administration (Okun et al., 2010) of poly I:C on cognitive function.
The poly I:C-induced fever in rats is partially dependent on IL-1b
(Fortier et al., 2004) and temperature and sleep/wake regulation
have been described to be altered in IFNAR1/ mice (Traynor
et al., 2006), but there has been little investigation of the role of
IFN-I in poly I:C-induced sickness behaviour and neuroinﬂamma-
tory changes. Here, we investigated the role of IFN-I in the CNS
effects of systemic poly I:C using IFNAR1/mice and C57BL6 con-
trols. We show a role of IFNAR1 in hypoactivity, anhedonia,
hypothermia and anorexia upon systemic challenge with this dou-
ble stranded RNA viral mimetic. We also observed signiﬁcant
impacts of IFNAR deﬁciency on IL-6 expression. Understanding
the interactions between these cytokines in mediating the CNS
effects of viral infection may be important in mitigating the dis-
comforting effects of acute illness and may provide insights into
the acceleration of chronic neurodegenerative disease by the stim-
ulation of acute anti-viral responses (Field et al., 2010).2. Methods
All animal procedures were performed under licence from the
Irish Department of Health & Children after a full ethical review
by the TCD animal research ethics committee, in compliance with
the Cruelty to Animals Act, 1876 and the European Community
Directive, 86/609/EEC. Female C57BL/6 mice (Harlan, Bicester,
UK) were housed in groups of ﬁve, with food and water ad libitum.
Female mice were used to minimise aggression. Animals were kept
at 21 C with 12:12 h light-dark cycle. IFNAR1/ mice were
obtained from Prof Paul J Hertzog of Monash Medical Centre,
Monash University, Clayton, Victoria, Australia. Generation of
mutant mice was as previously described (Hwang et al., 1995):
129Sv ES cells were transferred into the Balb/C background and
offspring backcrossed onto a C57BL6/J background for >7
generations.2.1. Systemic inﬂammatory challenges
2.1.1. Poly I:C
Poly I:C obtained from Amersham Biosciences (Little Chalfont,
Buckinghamshire, UK) was prepared for injection by re-suspension
in sterile saline, and was heated to 50 C at a concentration of
2 mg/ml and was allowed to cool to room temperature to ensure
proper annealing of double-stranded RNA. Poly I:C was stored at
20 C until use. Experimental groups were challenged intraperi-
toneally (i.p.) with either poly I:C (12 mg/kg) or sterile saline,
based on our prior observations with this dose (Cunninghamet al., 2007). Blood and hypothalamic and hippocampal tissues
were collected, from a separate group of animals, 3 h post-poly
I:C challenge for analysis of inﬂammatory markers, and also at
1 h in a subset of the study.
2.1.2. Cytokines
Experimental groups were injected with recombinant mouse IL-
6 i.p (Peprotech, Rocky Hill, NJ, USA) at a dose of 50 lg/kg prepared
in 0.9% sterile saline, judged to be a mild dose based on our own
prior observations (Skelly et al., 2013 and references therein).
Control animals were injected with sterile saline (Sigma, Poole,
UK) 10 ml/kg body weight. Additional animals were injected with
recombinant mouse IFN-b i.p (PBL Interferon source, NJ, USA) at
a dose of 25,000 units or with vehicle solution, phosphate buffered
saline containing 0.037% Glycerol and 0.0094% BSA, 10 ml/kg body
weight.
2.2. Behavioural & sickness analyses
2.2.1. Burrowing
Black plastic cylinders, 20 cm long, 6.8 cm diameter, sealed at
one end, were ﬁlled with 300 g of normal diet food pellets, and
placed in individual mouse cages. The open end was raised by
3 cm above the ﬂoor preventing non-purposeful displacement of
the contents. Mice were placed individually in the cages at appro-
priate times post-poly I:C, IFN-b or IL-6 challenges. The food
remaining in the cylinders after 2 h was weighed and the amount
displaced (burrowed) was calculated. Baseline tests were run 24 h
before inﬂammatory challenges. Burrowing is typically performed
during or just before the dark phase and is thus generally per-
formed between 6 and 12 h post-poly I:C or cytokine challenge.
2.2.2. Open ﬁeld
To investigate locomotor and rearing activity the open ﬁeld task
was used. Brieﬂy, mice were placed in a box
(58 cm  33 cm  19 cm) 3 h post-poly I:C or IL-6 challenges and
9 h post IFN-b. The former times were chosen on the basis of
observed suppression of open ﬁeld activity in prior poly I:C studies
(Cunningham et al., 2007) while the latter was chosen after observ-
ing no suppression at early time points but some suppression of
activity during the peak dark phase activity in pilot IFN-b experi-
ments. Rearing and square crossings (distance travelled) were
recorded for 3 min. Baseline tests were run 24 h before challenges.
2.2.3. Temperature
Body temperature was measured using a rectal probe (RET-3-
ISO Rectal Probe Physitemp, NJ) on three occasions in the week
prior to poly I:C injections to habituate mice to this procedure.
Mice were then assessed at the time of injection and at intervals
afterwards. These intervals were 3, 6 and 9 h post-poly I:C, based
on prior experiments (Cunningham et al., 2007) and were not
changed signiﬁcantly (4, 9, and 24 h) post-IFN-b challenges.
2.2.4. Body weight
Body weight was recorded at the time of injection and at the
following intervals afterwards; 12, 28 and 48 h post-poly I:C and
IL-6 challenges. For the IFN-b challenges body weight was mea-
sured at 7 and 24 h post -challenge. A timeline for the assays per-
formed during poly I:C challenges is shown in Fig. 1.
2.3. RNA extraction and quantitative PCR
Mice were terminally anaesthetised (i.e administered a fatal
dose of anaesthetic) using Euthatal and transcardially perfused
with heparinised saline 3 h post-challenge with poly I:C or IFN-b.
The hypothalami and hippocampi were collected and stored at
Fig. 1. Experimental timeline. Schematic showing the timeline of treatments and parameters measured during the poly I:C treatment experiments conducted in the current
studies. Burrows were analysed only in the ±IL-6 experiment and are shown in blue. Tissue for inﬂammatory mediator analysis (*) was collected from a separate cohort. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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RNeasy Plus mini kits (Qiagen, Crawley, UK) and yields were
determined by spectrophotometry at 260 nm as previously
described (Murray et al., 2011). cDNA synthesis was performed
using a High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Warrington). 200 ng of total RNA was reverse tran-
scribed in a 10 ll reaction volume. One microlitre of the RT
reaction (equivalent to 20 ng of RNA) was used for PCR.
Quantiﬁcation was carried out as previously described
(Cunningham et al., 2005) after normalisation to GAPDH
expression.2.4. ELISA
IFNAR1/ and WT animals were terminally anaesthetised 3 h
post-poly I:C (12 mg/kg i.p.), IFN-b (25,000 units, i.p.) or saline
challenges and the thoracic cavity opened and blood was collected
into heparinised tubes directly from the right atrium of the heart.
Blood was centrifuged to remove cells and the remaining plasma
was aliquoted and stored at 20 C. Samples from IFNAR1/ and
WT animals were analysed for plasma IL-6 and TNF-a (R&D
Systems U.K) and IFN-b (PBL Biomedical Laboratories, USA) using
commercially available enzyme-linked immunosorbent assay kits,
as per manufacturer guidelines.2.5. Western blotting
Hippocampal punches, weighing 20–30 mg were homogenised
in 100 ll of lysis buffer (50 mM Tris–HCl, 150 mM NaCl, 1%
Triton 10) with protease and phosphatase inhibitors. The homo-
genate was then centrifuged at 4 C for 10 min at 10,000 rpm. Total
protein content was quantiﬁed using a DC protein Assay (Biorad)
and samples were boiled in loading buffer containing b-mercap-
toethanol. 50 lg of each lysate was loaded onto a 10% SDS–PAGE
gel and the proteins were transferred to a PVDF membrane follow-
ing separation by electrophoresis. Membranes were blocked in 5%
non-fat milk in TBS and 0.1% Tween-20 for 1 h at room tempera-
ture. The membranes were then incubated overnight at 4 C with
primary antibodies STAT1 (SC346, Santa Cruz), phosphorylated
STAT1 (#9167 cell signalling) at 1/1000 dilution and Beta Actin
(A5441 Sigma) at 1/5000 dilution. Membranes were then washed
in TBS-T and incubated with secondary antibodies: goat anti-rabbit
(P0448 Dako, 1/1000 dilution) for both STAT1 and phosphorylated
STAT1 and goat anti-mouse (Jackson, 1/10,000 dilution) for Beta
Actin. Membranes were then developed using Supersignal West
Dura Extended Duration ECL (Pierce) and quantiﬁed using Image
J software (imagej.nih.gov/ij/).2.6. HPLC
Tryptophan and kynurenine were measured in serum and brain
samples using HPLC coupled to UV/ﬂuorescence detection as previ-
ously described (Gibney et al., 2014). Samples were diluted in
mobile phase containing 50 nM glacial acetic acid, 100 mM zinc
acetate (Sigma, Ireland) and 3% acetonitrile dissolved in double-
distilled NANOpure water HPLC grade H2O (Sigma, Ireland) at pH
4.9. Plasma was diluted 1:1 in mobile phase containing 6% perchlo-
ric acid (for protein precipitation) spiked with 200 ng/20 ll of N-
methyl 5-HT (Sigma, Ireland) as internal standard. Samples were
weighed and sonicated in mobile phase containing 6% perchloric
acid spiked with 200 ng/20 ll of N-methyl 5-HT as internal stan-
dard. Samples were centrifuged at 20,000 rpm for 20 min and the
supernatants were placed into new eppendorf tubes, using a syr-
inge ﬁtted with a 0.45 lM ﬁlter (Phenomenex, UK). 20 ll of the ﬁl-
tered supernatant was injected using a waters autosampler and a
Reverse Phase analytical column (Kinetex™ Core Shell
Technology column with speciﬁc area of 100 mm  4.6 mm and
particle size of 2.6 lm, Phenomenex, UK) was used for separation
of metabolites. A PDA-UV detector (Shimadzu SPD-M10A VP), cal-
ibrated to integrate at 230, 250 and 365 nM, as well as a ﬂuores-
cent detector (Shimadzu RF-20A XS prominence ﬂuorescence
detector), set to excitation wavelength 254 nM; emission wave-
length 404 nM, were used to detect tryptophan and kynurenine.
Chromatographs were generated by CLASS-VP software
(Shimadzu, UK). Results are expressed as ng of analyte per ml of
plasma and ng of analyte per gram of tissue.
2.7. Statistical analysis
2.7.1. Poly I:C challenges
We made a priori predictions that poly I:C would produce
robust suppression of rearing activity at 3 h and hypothermia at
8 h. Therefore we performed two-way ANOVA with strain and
treatment as factors for these analyses. Body weight was analysed
by three-way ANOVA with strain and treatment as between sub-
jects factors and time as within subjects factor. All ELISA, RT-PCR,
HPLC and Western blots were also analysed by two-way ANOVA
or Students t-test.
2.7.2. IFN-b challenges
Open ﬁeld rearing activity and burrowing in saline and IFN-b-
treated animals was analysed by Students t-test at 9 and 7 h
respectively. IL-6 protein expression and mRNA level were anal-
ysed at 3 h by Students t-test.
2.7.3. IL-6 challenges
Burrowing, rears and body weight responses to acutely admin-
istered IL-6 were analysed by three-way ANOVA with strain and
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sure. For poly I:C ± IL-6 challenges we had a priori predictions and
performed two-way ANOVA analysis of burrowing at 9 h and rear-
ing at 3 h. Body weight data were analysed using three-way
ANOVA with strain, treatment and time as factors.3. Results
3.1. Poly I:C-induced type I interferons and sickness behaviour
Poly I:C induced robust hypothalamic expression of IFN-b
mRNA but not IFN-a mRNA (Fig. 2a) and induced some features
of sickness in all treated animals. IFNAR1/ mice appeared to
show less hunched posture and piloerection than WT animals
when challenged with poly I:C. We quantiﬁed the sickness beha-
viour response using a number of objective measures.
Temperature was measured, by rectal probe, at 3, 6, and 9 h
post-poly I:C challenge and early measures showed variability
and possible stress-related hyperthermia in most animals.
Nonetheless, WT poly I:C-treated mice showed signiﬁcant
hypothermia at 9 h and this was not robust in poly I:C-treated
IFNAR1/ mice (Supplementary Fig. 1). Based on prior studies
(Cunningham et al., 2007), we made an a priori prediction of robust
hypothermia at 9 h and two-way ANOVA at 9 h showed a signiﬁ-
cant effect of treatment (F = 13.91, df 1,40, p = 0.0006), no effect
of strain (F = 1.37, df 1,40, p = 0.2489) but a signiﬁcant interaction
between treatment and strain (F = 8.22, df 1,40, p = 0.0066) indicat-
ing the impaired hypothermic response in IFNAR1/ mice.
Rears in the open ﬁeld were recorded for 3 min, 3 h post-chal-
lenge with poly I:C or saline. There was a robust decrease in the
number of rears in poly I:C-treated mice but this was less marked
with IFNAR1/ poly I:C-treated mice compared to WT poly I:C-
treated (Fig. 2b). Two-way ANOVA revealed a signiﬁcant effect of
strain (F = 4.51, df 1,40, p = 0.04) and of treatment (F = 14.85, df
1,40, p = 0.0004) but no signiﬁcant interaction (F = 0.88, df 1,40,
p = 0.3549). Bonferroni post-hoc analysis indicated that suppres-
sion of rears by poly I:C was signiﬁcantly more robust in WT ani-
mals than in IFNAR1/ animals (p < 0.05).
All poly I:C-treated mice showed a marked reduction in weight
but recovery was signiﬁcantly better in IFNAR1/ mice at 48 h
(Fig. 2c). Three-way ANOVA with strain, treatment and time as fac-
tors revealed no signiﬁcant effect of strain (F = 0.23148, df 1,43,
p = 0.6331) but a signiﬁcant effect of treatment (F = 118.4, dfFig. 2. Poly I:C-induced type I interferons and sickness behaviour inWT and IFNAR1/m
poly I:C (12 mg/kg i.p.). (b) The sickness behaviour response of C57BL/6 and IFNAR1/m
Differential effects of poly I:C on (b) rearing were assessed using two-way ANOVA (with
using 3 way ANOVA analysis with time, treatment and strain as factors in WT and IF
WT + pI:C, n = 13 for IFNAR1/ + saline and n = 14 for IFNAR1/ + pI:C. Full ANOVA anal
hoc are denoted by ⁄⁄p < 0.01 and ⁄p < 0.05 w.r.t WT + pI:C .1,43, p < 0.0001) and of time (F = 102.95, df 3,43, p < 0.0001) and
an interaction of all three factors (F = 12.99, df 1,43, p < 0.0001).
Therefore activity of IFN-I inﬂuences the time-course of recovery
during poly I:C-induced sickness.3.2. Systemic and CNS cytokine responses
3.2.1. Plasma
Plasma from WT and IFNAR1/ mice 3 h post-challenge with
poly I:C or saline was analysed for systemic levels of pro-inﬂam-
matory cytokines (IL-6, TNF-a, IL-1b and IFN-b) by ELISA (Fig. 3).
The plasma concentrations of IL-6, TNF-a, IL-1b and IFN-b in the
saline-treated animals were below detection levels. There was
almost complete ablation of the IL-6 response in poly I:C-treated
IFNAR1/ mice. Two-way ANOVA analysis of plasma IL-6 levels
revealed a signiﬁcant effect of treatment (F = 28.18, df 1,18,
p < 0.0001) and of strain (F = 21.04, df 1,18, p = 0.0002) and an
interaction between treatment and strain (F = 21.04, df 1,18,
p = 0.0002). Analysis of plasma TNF-a, IL-1b and IFN-b by two-
way ANOVA demonstrated a signiﬁcant effects of treatment
(FP 42.03, df 1,18, p < 0.0001) but no effects of strain and no inter-
action, indicating that poly I:C-induced increases in plasma TNF-a,
IL-1b and IFN-b are not affected by IFNAR1.3.2.2. Brain
Hypothalamic and hippocampal brain regions were also
extracted from WT and IFNAR1/ mice 3 h post-challenge with
poly I:C or saline. IFN-b, IL-6, TNF-a and IL-1b expression was mea-
sured by RT-PCR. As in the plasma, there was a near- complete
ablation of IL-6 in the IFNAR1/ poly I:C-treated compared to
the WT poly I:C-treated in the hypothalamus (Fig. 3e) and in the
hippocampus (Fig. 3i). Two-way ANOVA of IL-6 mRNA revealed a
signiﬁcant effect of treatment (F = 32.08, df 1,18, p < 0.0001), of
strain (F = 28.18, df 1,18, p < 0.0001) and an interaction
(F = 27.39, df 1,18, p < 0.0001) of these two factors in the hypotha-
lamus and this effect was replicated in the hippocampus: treat-
ment (F = 26.75, df 1,18, p < 0.0001), strain (F = 22.46, df 1,18,
p < 0.0002) and interaction of strain and treatment (F = 21.79, df
1,18, p < 0.0002).
Conversely, TNF-a was increased by poly I:C in the hypothala-
mus (Fig. 3f) and the hippocampus (Fig. 3j) in both WT and
IFNAR1/ mice. Two-way ANOVA analysis shows a signiﬁcant
effect of treatment (F = 428.72, df 1,18, p < 0.0001) but no effectice. (a) The hypothalamic transcription of IFN-a and IFN-bwere assessed at 6 h post-
ice to poly I:C was assessed (b) open ﬁeld rearing activity and (c) % body weight loss.
strain and treatment as between-subjects factors) and (c) body weight was assessed
NAR1/ mice. Data are expressed as mean ± SEM, n = 5 for WT + saline, n = 8 for
ysis appears in the main text. Statistically signiﬁcant differences by Bonferroni post-
Fig. 3. Poly I:C-induced systemic and CNS synthesis of inﬂammatory cytokines. ELISA analysis of plasma IL-6, TNF-a, IL-1b and IFN-b (a-d) and CNS cytokine transcription 3 h
after intraperitoneal challenge with poly I:C (12 mg/kg). Analysis of transcripts is shown for hypothalamus (e–h) and hippocampus (i–l). Data are expressed as mean ± SEM,
n = 5 for WT and n = 6 for IFNAR1/. Comparisons of pI:C treatment for WT and IFNAR1/mice were carried out by two-way ANOVA, with treatment and strain as factors.
Main effects of treatment are denoted by ###p < 0.001, ##p < 0.01 and #p < 0.05 and interactions between treatment and strain are denoted by ⁄⁄⁄p < 0.001 and ⁄⁄p < 0.001.
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or treatment (F = 0.52, df 1,18, p = 0.4782). Similarily in the hip-
pocampus (Fig. 3j), two-way ANOVA shows poly I:C induced
increases in TNF-a, with a signiﬁcant effect of treatment
(F = 53.39, df 1,17, p < 0.0001) but no effect of strain (F = 0.24, df
1,17, p = 0.6284) and no interaction between strain and treatment
(F = 0.64, df 1,17, p = 0.4362), indicating that poly I:C-induced
increases in the expression of TNF-a and IFN-b are not affected
by IFNAR1.
IL-1bwas also increased by poly I:C in the hypothalamus, but to
a greater degree in IFNAR1/ than WT mice (Fig. 3g). There was a
signiﬁcant effect of treatment (F = 57.17, df 1,18, p < 0.0001) and of
strain (F = 10.83, df 1,18, p = 0.0041) and an interaction between
treatment and strain (F = 10.65, df 1,18, p = 0.0043). In the hip-
pocampus (Fig. 3k) poly I:C treatment once again had a signiﬁcant
effect on IL-1b expression (F = 12.78, df 1,17, p < 0.0023) but there
was no effect of strain (F = 1.24, df 1,17, p = 0.2813) and no interac-
tion (F = 0.45, df 1,17, p = 0.9722) indicating that the poly I:C
induced increase in IL-1b mRNA is exacerbated in IFNAR1/ mice,
but only in the hypothalamus.
Poly I:C robustly induced IFN-b in the hypothalamus of bothWT
and IFNAR1/ mice (Fig. 3h). There was a signiﬁcant effect oftreatment (F = 17.45, df 1,17, p < 0.0006) but no effect of strain
(F = 0.46, df 1,17, p = 0.5059) and no interaction (F = 0.45, df 1,17,
p < 0.5136). In the hippocampus, poly I:C induced IFN-b (Fig. 3l)
with a main effect of treatment (F = 16.89, df 1,16, p < 0.0008),
strain (F = 7.91, df 1,16, p < 0.0125) and an interaction of
strain  treatment (F = 4.58, df 1,16, p < 0.0482), indicating a lack
of poly I:C-induced IFN-b response in the hippocampus but not
the hypothalamus of IFNAR1/ mice.
These results suggest that IFNAR1 expression appears to be nec-
essary for robust plasma and CNS IL-6 responses to poly I:C and for
the full expression of sickness behaviour, but not for IL-1b nor TNF-
a responses. This is not the case for IL-6 and sickness behaviour
responses to LPS in IFNAR1/ mice: IL-6 levels and locomotor
activity are similarly altered by LPS in WT and IFNAR1/ mice
(Supplementary Fig. 2). There is evidence for an exaggerated
hypothalamic IL-1b response to poly I:C in IFNAR1/ mice.
3.3. Does acutely induced IFN-b induce IL-6 and sickness behaviour?
The milder sickness behaviour and loss of poly I:C-induced IL-6
in IFNAR1/ animals suggested a role for IFN-I in IL-6 expression.
Therefore we examined whether systemically administered IFN-b
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plasma IL-6 (Fig. 4a; p < 0.05 by unpaired Student’s t test) and ele-
vated expression of IL-6 mRNA in the hypothalamus compared to
vehicle-injected controls (Fig. 4b; p < 0.05 by unpaired Student’s t
test). However, this increase in IL-6 was not replicated in the hip-
pocampus and levels of plasma IL-6 and brain IL-6 mRNA were
trivial compared to those induced by poly I:C (Fig. 4a and b).
A number of measures of sickness behaviour were assessed.
There were no effects of IFN-b (25,000 units) on body temperature
or body weight (data not shown). Open ﬁeld activity was recorded
for 3 min, 9 h post-challenge with IFN-b or vehicle (Fig. 4c) after
pilot experiments indicated mild effects on activity only in the dark
phase. There was a slight decrease in activity in the IFN-b-treated
mice with respect to controls, p < 0.0011 by unpaired Student’s t
test. Burrowing activity was measured at baseline and we made
an a priori prediction of impairment at 7 h post-challenge with
IFN-b (25,000 units; Fig. 4d). Students t-test at 7 h showed a small
but statistically signiﬁcant effect of treatment (p = 0.0318).
Having found that IFN-b could drive very limited IL-6 and sick-
ness behaviour it was also necessary to establish the plausibility of
the idea that acutely induced IFN-b was necessary for poly I:C-in-
duced IL-6 (i.e. whether IFN-b was expressed signiﬁcantly earlier
than IL-6 after poly I:C stimulation in vivo). We examined the
sequence of expression of IL-6 and IFN-b in the plasma and hip-
pocampus of WT and IFNAR1/ mice 1 and 3 h post-challenge
with saline or poly I:C (Fig. 4e–h). There was no detectable IL-6
or IFN-b in the plasma of saline-treated mice but 1 h post-poly
I:C there was measureable plasma IL-6 and IFN-b and both these
cytokines increased substantially in wild-type mice at 3 h.
However, IL-6 concentration showed no further increase in the
IFNAR1/mice while IFN-b continued to rise at 3 h in both strains
(Fig. 4e and f). Two-way ANOVA of plasma IL-6 showed aFig. 4. The role of acutely increased IFN-b in induction of IL-6 and sickness behaviour.
C57BL/6 mice 3 h post-IFN-b challenge (25,000 units, i.p), compared to that induced by po
Student’s t test, n = 4 for WT + vehicle and n = 5 for WT + IFN-b. The sickness behaviou
(expressed as % of baseline squares crossed at 9 h) and (d) burrowing at 7 h. Data are exp
n = 15 for WT + IFN-b. IL-6 and IFN-b levels in the plasma (e, f) and expression in the hipp
expressed as mean ± SEM and were analysed by two-way ANOVA with strain and treatme
n = 4 for IFNAR1/ + saline, n = 4 IFNAR1/ + pI:C 1 h and n = 5 for IFNAR1/ + pI:C 3 hsigniﬁcant effect of strain (F = 13.41, df 1,25, p = 0.0012) and inter-
action between treatment and strain (F = 15.50, df 2,25,
p = 0.0001). Bonferroni post-hoc analysis showed a signiﬁcant dif-
ference between poly I:C and saline at 3 h in wild-type
(p < 0.001) but not in IFNAR1/ mice. Two-way ANOVA for IFN-b
showed equivalent responses to poly I:C in both strains (i.e. a sig-
niﬁcant effect of treatment (F = 44.39, df 2,25, p < 0.0001) but no
signiﬁcant effect of strain (F = 0.24, df 1,25, p = 0.6318), or interac-
tion between these two factors (F = 0.39, df 2,25, p = 0.6818) indi-
cating that IFNAR1 is necessary for the full poly I:C-induced
plasma IL-6 response but not the plasma IFN-b response.
In the hippocampus IL-6 mRNA was not yet signiﬁcantly
induced in either strain at 1 h and was elevated only in the WT
mice at 3 h post-poly I:C (Fig. 4g). Two-way ANOVA of IL-6 expres-
sion, with strain and treatment as factors, showed a signiﬁcant
effect of strain (F = 23.26, df 1,21, p < 0.0001) and treatment
(F = 30.87, df 2,21, p = 0.0001) and an interaction between treat-
ment and strain (F = 15.50, df 2,25, p < 0.0001). Bonferroni post-
hoc analysis showed a signiﬁcant difference in WT poly I:C-treated
at 3 h when compared to controls (p < 0.001). The expression of
IFN-b in the hippocampus was different to that seen in the plasma
(Fig. 4h). There was detectable IFN-b expression present at 1 h in
both strains, however IFN-b expression increased at 3 h post-poly
I:C in WT mice but not in IFNAR1/ mice. There was a signiﬁcant
effect of strain (F = 5.10, df 1,21, p = 0.0347), treatment (F = 4.84, df
2,21, p = 0.0186), but no signiﬁcant interaction (F = 2.25, df 2,21,
p = 0.1303).
Thus, similar to plasma IL-6, the poly I:C-induced hippocampal
IL-6 response is facilitated by IFNAR1. Moreover, in contrast to the
plasma IFN-b response, poly I:C-induced hippocampal IFN-b is also
mediated by IFNAR1 activity. Nonetheless, there was little evi-
dence that acutely induced IFN-bmight be responsible for the polyPlasma IL-6 (a) and IL-6 expression in the hypothalamus and hippocampus (b) of
ly I:C (12 mg/kg). Data are expressed as mean ± SEM and were analysed by unpaired
r response of C57BL/6 mice to IFN-b (25,000 units, i.p.) on (c) open ﬁeld activity
ressed as mean ± SEM and were analysed by Students t-test, n = 17 for WT + vehicle,
ocampus (g,h) 1 and 3 h post-poly I:C challenge in WT and IFNAR1/mice. Data are
nt as factors, n = 5 for WT + saline, n = 4 for WT + pI:C 1 h, n = 5 for WT + pI:C 3 h and
. Bonferroni post-hoc are denoted by ⁄⁄⁄p < 0.001 and ⁄⁄p < 0.001.
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that IFNAR1 facilitates full IL-6 expression, perhaps through basal
low level IFN-I activity.3.4. STAT1 expression
It has been reported that STAT1 can contribute to the expres-
sion of IL-6 (Lee et al., 2006; Chaudhuri et al., 2008). Western blot
analysis of STAT1 and phosphorylated STAT1 was performed in WT
and IFNAR1/ mice to assess whether lower basal levels of STAT1
in IFNAR1/ mice might associate with the lack of IL-6 in the
IFNAR1/ mice. STAT1 activity drives new transcription of
STAT1 mRNA (Satoh and Tabunoki, 2013; Cheon and Stark, 2009)
and we have thus also assessed stat1 mRNA as an additional mea-
sure of STAT1 activity when phospho STAT1 levels were too low to
detect.
Western blotting showed that basal total STAT1 is higher in the
WT than IFNAR1/mice (Fig. 5a) and quantiﬁcation by densitom-
etry shows this difference to be signiﬁcant (Student’s t test,
p = 0.0015, Fig. 5c). Total and phospho-STAT1 were also assessed
at 1 and 3 h post-poly I:C in WT and IFNAR1/ mice (Fig. 5b).
Quantiﬁcation (Fig. 5c) and analysis by two-way ANOVA with
strain and treatment as factors demonstrate a signiﬁcant effect of
strain (F = 16.31, df 1,17, p = 0.0009) and a signiﬁcant interaction
(F = 7.61, df 1,17, p = 0.0134) but no effect of treatment (F = 0.01,
df 1,17, p = 0.9389) indicating that poly I:C does not signiﬁcantly
alter total STAT1 levels within 3 h. STAT1 became phosphorylated
(i.e. activated) at 3 h in all WT + poly I:C mice tested and was never
detected in any other treatment/strain combination.
STAT1, which can translocate to neuronal nuclei upon phospho-
rylation (Gautron et al., 2003), has been shown to induce transcrip-
tion of stat1 mRNA (Satoh and Tabunoki, 2013; Cheon and Stark,Fig. 5. Expression of total and phosphorylated STAT1 in WT and IFNAR1/mice. Wester
blot analysis of STAT1 and phosphorylated STAT1 in WT and IFNAR1/ mice post-poly
IFNAR1/mice and levels of STAT1 at 1 and 3 h post-poly I:C (c). Signiﬁcant differences b
expressed as mean ± SEM and analysed by two-way ANOVA with treatment and strain as
for IFNAR1/ + saline, n = 4 for IFNAR1/ + pI:C 1 h, n = 5 for IFNAR1/ + pI:C 3 h. Signiﬁ
saline-treated controls.2009) and therefore we also used hippocampal stat1 mRNA as a
readout of STAT1 activity, when levels of phosphoSTAT1 were too
low to detect (Fig. 5d). We found lower stat1 mRNA expression at
baseline in IFNAR1/mice with respect to WT mice (i.e. in saline-
treated mice) and an acute induction of stat1 mRNA by 3 h.
Predictably, this increase was visible only in WT polyI:C-treated
animals. Two-way ANOVA showed a signiﬁcant effect of strain
(F = 149.93, df 1,15, p < 0.0001), treatment (F = 84.10, df 1,15,
p < 0.0001) and a signiﬁcant interaction (F = 49.98, df 1,15,
p < 0.0001). Bonferroni post-hoc analysis revealed poly I:C treat-
ment signiﬁcantly increased STAT1 expression at 3 h, only in WT
mice (p < 0.001 with respect to saline-treated controls), indicating
that poly I:C-induced increases in hippocampal STAT1 expression
are mediated by IFNAR1.3.5. Genotype-dependent differences in basal and poly I:C-induced
expression of inﬂammatory transcripts
Given the basal differences in STAT1 expression, we predicted
that there may be changes in basal levels of important STAT1-de-
pendent inﬂammatory transcripts. A number of inﬂammatory tran-
scripts with reported STAT1-dependent regulation were examined
in the hippocampus of WT and IFNAR1/mice (Fig. 6a). Interferon
regulatory factor 7 (IRF7) is a transcription factor that is speciﬁ-
cally induced by type I IFN action (via STAT1). CCL2-chemokine
(C-C motif) ligand 2 (or monocyte chemoattractant protein-1)
recruits monocytes, memory T cells, and dendritic cells to the sites
of inﬂammation. Indoleamine-2,3-dioxygenase (IDO) is an enzyme
that converts tryptophan to kynurenine. Cyclo-oxygenase 2 (COX-
2) is a key prostaglandin biosynthetic enzyme and interleukin 10
(IL-10) is a key anti-inﬂammatory cytokine. Basal IRF7 and CCL2
are lower in IFNAR1/ than WT when expressed as a fraction ofn blot of basal STAT1 in WT and IFNAR1/ hippocampal homogenates (a). Western
I:C challenge at 1 and 3 h (b). Quantitative histogram of basal STAT1 in WT and
y Students t test are denoted by ⁄⁄p = 0.0015. Expression of stat1 mRNA (d). Data are
factors; n = 5 for WT + saline, n = 4 for WT + pI:C 1 h, n = 5 for WT + pI:C 3 h and n = 5
cant main effect of treatment by Bonferroni post-hoc is denoted by ⁄⁄⁄p < 0.001 w.r.t.
Fig. 6. Differential basal and poly I:C-induced expression of inﬂammatory transcripts in WT and IFNAR1/mice. (a) Basal expression of multiple inﬂammatory transcripts in
IFNAR1/mice are expressed as a fraction of WT expression levels and comparisons between WT and IFNAR1/ were made by Student’s t tests, with statistical signiﬁcance
denoted by +p < 0.0001 and #p = 0.0021. (b–f) Expression of the same transcripts 3 h post-challenge with saline or poly I:C (12 mg/kg i.p.): (b) IRF7, (c) CCL2, (d) IDO, (e) COX-2
and (f) IL-10. Data are expressed as mean ± SEM and analysed by two-way ANOVA with treatment and strain as factors, n = 5 for WT and n = 6 for IFNAR1/. Signiﬁcant
interactions between strain and treatment are denoted by ⁄⁄⁄p < 0.001 and a signiﬁcant main effect of strain is denoted by ⁄p < 0.05 (d).
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lower basal IRF7 (p < 0.0001) and CCL2 (p = 0.0021) in IFNAR1/
and lower levels of IDO that did not reach statistical signiﬁcance
(p = 0.1156). Neither COX 2 (p = 0.1454) nor IL-10 (p = 0.5340)
were lower at basal levels.
Despite this lower basal level of CCL2, poly I:C still induces
increased CCL2 expression in IFNAR1/mice, but it remains lower
than that observed in WT mice (Fig. 6c). Two-way ANOVA analysis
revealed a signiﬁcant effect of strain (F = 26.65, df 1,18, p < 0.0001),
treatment (F = 47.56, df 1,18, p < 0.0001) and a signiﬁcant interac-
tion between strain and treatment (F = 25.28, df 1,18, p < 0.0001).
Transcription of the kynurenine biosynthetic enzyme indolea-
mine-2,3-dioxygenase (IDO), was analysed. Two-way ANOVA of
IDO expression in the hippocampus (Fig. 6d) showed a signiﬁcant
effect of strain (F = 15.14, df 1,15, p = 0.0014) but no effect of treat-
ment (F = 0.01, df 1,15, p = 0.9335) and no interaction (F = 0.02, df
1,15, p = 0.9023), indicating a decrease in basal hippocampal IDO
expression in IFNAR1/ mice and no poly I:C-induced increase
(at 3 h).
COX-2 and IL-10 expression (Fig. 6e and f) are similar in WT and
IFNAR1/ at baseline but are less robustly induced 3 h post-poly
I:C in IFNAR1/. Two way ANOVA analysis of COX-2 expression
also showed a signiﬁcant effect of strain (F = 7.95, df 1,18,
p = 0.0113), treatment (F = 29.70, df 1,18, p < 0.0001) and a signiﬁ-
cant interaction (F = 13.75, df 1,18, p = 0.0016). Two way ANOVA
analysis of IL-10 expression showed a signiﬁcant effect of treat-
ment (F = 7.04, df 1,15, p = 0.0181) but not of strain (F = 2.06, df
1,15, p = 0.1718) and no interaction (F = 3.40, df 1,15, p = 0.0850)
indicating that the poly I:C-induced increase in hippocampal
COX-2 and IL-10 expression is attenuated in IFNAR1/ mice.
Therefore, while the expression of IRF7, CCL2, IDO, COX-2 and
IL-10 are all signiﬁcantly different in poly I:C-treated IFNAR ani-
mals with respect to wild-types, lower basal expression of IRF7,
CCL2 and IDO certainly contributes to this effect.3.6. Kynurenine and tryptophan
We were unable to detect reliable levels of the IDO product
kynurenine by HPLC in either the hippocampus or frontal cortex
of these animals but levels of plasma kynurenine were clearly
higher in WT animals than in IFNAR1/ mice (Fig. 7a). Two-way
ANOVA shows a signiﬁcant effect of strain (F = 19.68, df 1,17,
p = 0.0004), treatment (F = 15.09, df 1,17, p = 0.0012) but no signif-
icant interaction (F = 4.39, df 1,17, p = 0.0515). Poly I:C induced a
robust elevation of kynurenine and of the kynurenine:tryptophan
ratio 24 h post-poly I:C (Fig. 7a and c) and this was signiﬁcantly
attenuated in IFNAR1/ mice. Two-way ANOVA of the
kynurenine:tryptophan ratio with strain and treatment as factors
shows a signiﬁcant effect of strain (F = 16.94, df 1,17, p = 0.0007),
treatment (F = 16.62 df 1,17, p = 0.0008) and a signiﬁcant interac-
tion (F = 4.49, df 1,17, p = 0.0491).
Thus, although a number of inﬂammatory markers show
restricted expression upon challenge with poly I:C, we cannot
attribute these differences solely to a lack of responsiveness to
acutely induced IFN-I: these animals express lower levels of these
markers at baseline, and although poly I:C-induced elevations
remain possible, robust elevation is facilitated by the expression
of IFNAR1.
3.7. IL-6 supplementation of poly I:C challenges
Returning to the original observations in this study: since IL-6
responses to poly I:C challenge are very signiﬁcantly deﬁcient,
we hypothesised that the sickness behaviour response to poly I:C
could be reconstituted by co-injecting exogenous IL-6 with poly
I:C in IFNAR1/ animals. To facilitate those experiments we ﬁrst
determined the effects of IL-6 alone in wild type and IFNAR1/
mice (Fig. 8a–c). For these experiments we omitted measurements
of core body temperature, since the effects of poly I:C were
Fig. 7. Levels of kynurenine pathway metabolites in WT and IFNAR1/mice. Levels
of kynurenine (a), tryptophan (b) and the ratio of kynurenine to tryptophan (c) in
the plasma of WT and IFNAR1/ mice were assessed by HPLC 24 h post-poly I:C
(12 mg/kg). Data are expressed as mean ± SEM and analysed by two-way ANOVA
with treatment and strain as factors, n = 5 for WT and n = 6 for IFNAR1/.
Signiﬁcant main effect of treatment is denoted by ##p < 0.01 and signiﬁcant
interaction between strain and treatment is denoted by ⁄p < 0.05.
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and replaced this with burrowing which is an extremely sensitive
measure of suppression of species typical behaviours (Deacon,
2006).
Burrowing activity was measured at 9 and 30 h, open ﬁeld
activity at 3 h and weight loss at 12, 24 and 48 h post-i.p. challenge
with IL-6 (50 lg/kg) or saline. There were no statistically signiﬁ-
cant effects of IL-6 treatment or strain on any of these parameters
using three way ANOVA (F 6 0.99, df 1,31, pP 0.3276).
Poly I:C induced a decrease in burrowing in all groups but, as
before, this decrease was attenuated in IFNAR1/ mice.
However, when IL-6 was co-administered with poly I:C, burrowing
in IFNAR1/ mice was decreased to levels equivalent to those in
WT + poly I:C animals (Fig. 8d). That is, IL-6 could reconstitute in
IFNAR1/ mice the full deﬁcit observed after poly I:C treatment
in WT animals. We made the a priori prediction that burrowing
would be maximally affected at 9 h and a two-way ANOVA analysisof the four poly I:C-treated groups at this time showed a main
effect of strain (F = 18.49, df 1,31, p = 0.0002), of IL-6 (F = 8.29, df
1,31, p = 0.0072) and an interaction between these factors
(F = 10.74, df 1,31, p = 0.0026). Bonferroni post-hoc analysis of these
data showed that when IL-6 was added simultaneously with poly
I:C, burrowing in the IFNAR1/ mice was no longer signiﬁcantly
different to poly I:C in the wild-type mice (p >> 0.05), while those
challenged with poly I:C + vehicle burrowed signiﬁcantly more
(p < 0.001 with respect to poly I:C + IL-6). Thus, the poly I:C-in-
duced decrease in burrowing, which is absent in the IFNAR1/,
is dependent on IL-6 levels.
We previously observed that poly I:C had less effect on rearing
activity at 3 h in IFNAR1/mice (Fig. 2b). Therefore, we examined
the ability of poly I:C + IL-6 to block rearing activity in IFNAR1/
mice, compared to poly I:C in WT mice (Fig. 8e). Examining the
effect of strain and co-administration of IL-6 at 3 h, two-way
ANOVA revealed a signiﬁcant effect of IL-6 co-treatment
(F = 4.43, df 1,35, p = 0.0425) and of strain (F = 19.57, df 1,35,
p < 0.0001) but no signiﬁcant interaction (F = 0.05, df 1,35,
p = 0.8213). Thus IL-6 exacerbates poly I:C-induced suppression
of rears, but does so equally in WT and IFNAR1/ animals. In other
words, both IL-6 and IFNAR1 inﬂuence poly I:C-induced decrease
in rears but these effects are independent of each other.
Poly I:C induced a marked weight loss in both strains as previ-
ously observed, but this recovered more quickly in IFNAR1/mice
(Fig. 2c). We addressed the possibility that the addition of IL-6 with
poly I:C might reconstitute the effect of poly I:C in WT animals.
However the addition of IL-6 did not slow the recovery of weight
in poly I:C-treated IFNAR1/ mice (Fig. 8f). A three-way ANOVA
of these data, using strain and IL-6 as between subjects factors
and time as the within subjects factor showed a main effect of
strain (F = 21.71, df 1,38, p < 0.0001) but no effect of IL-6
(F = 1.18, df 1,38, p = 0.283) and no interaction of strain and IL-6
(F = 1.37, df 1,38, p = 0.2496). Therefore the impact of type I inter-
feron on weight loss during poly I:C-induced sickness behaviour
does not appear to be mediated or modulated by IL-6.
Collectively these data show that IFNAR1 contributes to the
sickness behaviour responses in both IL-6-dependent and indepen-
dent mechanisms.4. Discussion
We demonstrate robust CNS expression of IFN-b, but not IFN-a,
after systemic poly I:C and have demonstrated that several CNS
behavioural and metabolic effects of poly I:C are attenuated in
IFNAR1/mice. The IL-6 response to poly I:C is profoundly dimin-
ished in IFNAR1/ mice and this is associated with a lack of basal
IFN-I and STAT1 expression. Addition of IL-6 is sufﬁcient to recon-
stitute full expression of some measures of altered CNS function
such as burrowing, but not anorexia. These data demonstrate
important interdependent and independent roles of IFNAR1 and
IL-6 signalling in the context of sickness and CNS behavioural
responses to systemic inﬂammation induced by viral mimetics.4.1. IFNAR1 deﬁciency inﬂuences the sickness behaviour response
Sickness behaviour is different in IFNAR1/ mice. The subjec-
tive observation that IFNAR1/ mice ‘appeared’ less sick, based
on less hunched posture and rufﬂed fur was borne out in objective
measures of the sickness response. We examined rearing beha-
viour in the open ﬁeld, an exploratory behaviour that was signiﬁ-
cantly reduced by poly I:C but less so in IFNAR1/. There was
also less marked hypothermia in IFNAR1 deﬁcient mice. The reduc-
tion of poly I:C-induced hypothermia in IFNAR1/ is consistent
with data showing protection in IFNAR1/ against the robust
Fig. 8. Sickness behaviour post-IL-6 and post-poly I:C ± IL-6 challenges. (a–c) The sickness response of C57BL/6 and IFNAR1/mice to saline or interleukin-6 (50 lg/kg i.p.),
as assessed by burrowing (a), rearing activity in the open ﬁeld (b) and % body weight loss (c). Data are expressed as mean ± SEM, n = 8 for WT + saline, n = 7 for WT + IL-6,
n = 10 for IFNAR + saline, n = 10 for IFNAR + IL-6. (d–f) The sickness response of C57BL/6 and IFNAR1/mice to poly I:C + vehicle (12 mg/kg i.p.) versus poly I:C + IL-6 (50 lg/
kg i.p.) challenges on burrowing (d), rearing (e) and body weight (f). Data are expressed as mean ± SEM, n = 11 for WT + pI:C and IFNAR + pI:C, n = 12 for IFNAR + pI:C + IL-6
and n = 5 for WT + pI:C + IL-6. Rearing activity at 3 h was analysed by two-way ANOVA (b,e) with strain and treatment as factors. Burrowing at 9 h (a,d) and body weight
change (c, f) were analysed by three-way ANOVA with strain, treatment and time as factors. * denotes signiﬁcant difference between IFNAR + pI:C + vehicle and
IFNAR + pI:C + IL-6 at 9 h after a signiﬁcant two-way ANOVA at that time (p < 0.05). # denotes signiﬁcant main effect of IL-6 treatment by two-way ANOVA (e).
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with inﬂuenza virus in wild type mice (Traynor et al., 2007).
Prior studies also indicate a hypothermic effect of IFN-a
(Sammut et al., 2001) and a hyperthermic effect of IFN-b during
the light phase (Billiau et al., 1980; Dinarello et al., 1984; Ohdo
et al., 1997). Burrowing is a rewarding behaviour in mice
(Deacon, 2006). Our studies indicate that poly I:C induced an effect
on burrowing, which may be described as anhedonic, although we
cannot rule out the possibility that this simply reﬂects reduced
activity in a more general sense. Nevertheless, the poly I:C-induced
burrowing deﬁcit was largely abolished in IFNAR1/ and this
effect was mediated via the deﬁcient IL-6 response in IFNAR1/
mice, which differs somewhat from the IL-6 dependence of the
locomotor activity deﬁcits. Some recent data suggest that
decreased wheel-running in poly I:C-treated animals is not pre-
vented by systemic administration of an anti-IFN-b antibody
(Matsumoto et al., 2008). The direct administration of IFN-b, in
the current study, had statistically signiﬁcant, but very mild effects
on open ﬁeld activity and burrowing (Fig. 4). These mild effects
may be explained by the rapid clearance of injected cytokines
(Abraham et al., 2010) but may also reﬂect the requirement for
IL-6 to mediate or contribute additively to IFNAR effects (Fig. 8).
Poly I:C is known to produce robust anorexia (Cunningham
et al., 2007). A clear poly I:C-induced anorexic effect was also expe-
rienced in IFNAR1/mice in the current study but its duration was
much shorter than in wild-type mice, indicating a signiﬁcant con-
tribution of IFN-I to anorexia. Poly I:C-treated animals remained
capable of rearing and climbing and, in previous studies, main-
tained muscle strength and motor coordination (Field et al.,
2010) and it is therefore highly likely that weight loss reﬂected
decreased drive to eat rather than inability to obtain food. This
effect was not altered by IL-6 addition, consistent with a direct role
for IFN-I in mediating this effect, in agreement with early reports of
effects of IFN-a on food intake (Segall and Crnic, 1990). Althoughmost animal studies of sickness-inducing IFN-I effect have
focussed on IFN-a, we only observed increased IFN-b in the current
study and there are human data to indicate that IFN-b produces
signiﬁcant fatigue and anorexia (Rinehart et al., 1986; Borden
et al., 2011). However, weight loss occurred rapidly in IFNAR1/
mice and therefore must be independent of IFN-I, perhaps occur-
ring via TNF-a, which is known to contribute to cachexia and
whose expression is increased by poly I:C and not signiﬁcantly
diminished in IFNAR1/ mice (Fig. 3).
In describing effects of IFNAR on sickness, it is important to
recognise that type I IFN is essential in combating viral infection
and the absence of the type I IFN response during active infection
would be predicted to, and indeed has been shown to, lead to
increased sickness as the animal fails to control the infection
(Kugel et al., 2009).4.2. Impaired IL-6 response to poly I:C in IFNAR1/ mice
In order to delineate why these behavioural and metabolic
responses in the CNS are different in animals unresponsive to type
I IFN, we ﬁrst assessed the cytokine proﬁle in blood and brain,
revealing some striking differences. The IL-6 response to poly I:C
was profoundly diminished in IFNAR1/ mice indicating that
robust IL-6 expression upon poly I:C challenge is type I IFN-depen-
dent. The simplest explanation of this effect would be that, in nor-
mal animals, poly I:C induces IFN-b, which in turn induces IL-6.
However this is not intuitive since NFjB is a key regulator of IL-6
and is induced rapidly after LPS, TNF-a or double stranded RNA
stimulation (Libermann and Baltimore, 1990) and indeed this
explanation does not ﬁt with the data in the current study.
Firstly, intraperitoneal challenge with IFN-b produced very limited
IL-6 expression in blood and brain, consistent with the limited evi-
dence for IFN-a/b directly inducing IL-6 (Ito et al., 1996). Secondly,
plasma analysis at 1 and 3 h post-poly I:C (Fig. 4) demonstrated
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ues to increase in WT animals at 3 h but this further increase in IL-
6 is absent in IFNAR1-deﬁcient mice. These data indicate that acute
IFN-b expression is not the signal that triggers IL-6 expression.
Rather, we propose that basal IFN-I expression is necessary to facil-
itate the robust expression of IL-6 upon exposure to poly I:C. There
is now ample evidence that low level actions of type I interferons
are essential to enhance cellular responses to subsequent stimuli
(Taniguchi and Takaoka, 2001) and these include optimisation of
both type I interferon responses but also responses to other cytoki-
nes such as IFN-c and IL-6 (Muller et al., 1994; Mitani et al., 2001).
It is also known that IFN-c-induced factors can synergise with TLR
agonists to produce optimal levels of TLR target genes and key
among these factors is STAT1, which synergises with NFjB to max-
imise inﬂammatory mediator output (Schroder et al., 2006). STAT1
activity is also a major signalling mechanism in type I interferon
actions and it has been described that cells that are IFNAR1/ pro-
vide less docking sites for STAT1 and STAT3, thus impairing STAT1/
3 and therefore also IL-6 and IFN-c signalling (Mitani et al., 2001).
However IFNAR1/ animals have suppressed levels of total STAT1
with respect to normal animals and this lower STAT1 has been
shown to result in lower expression of STAT1-dependent genes
stat1, irf1 and junB (Gough et al., 2010), providing a simpler expla-
nation of less efﬁcient expression of STAT1-dependent genes in
IFNAR1/ mice. Our data replicate, in the brain, this lower
STAT1 expression level, decreased STAT1 phosphorylation post-
poly I:C and the decreased transcription of the dependent gene
stat1 (Fig. 5). This suggests that basal STAT1 has a role in facilitat-
ing poly I:C-induced IL-6 in the CNS, probably in co-operation with
NFjB, which is also known to inﬂuence IL-6 expression after dou-
ble stranded RNA stimulation (Libermann and Baltimore, 1990).
JAK-STAT1 signalling has been shown to be sufﬁcient for IL-6
expression in macrophages treated with phosphatidic acid (Lee
et al., 2006) and IRF1 and NFjB have also been shown to co-oper-
ate, at low levels of expression, at the IL-6 promoter (Faggioli et al.,
1997). In HIV infection of cultured cells, the STAT1 inhibitor ﬂu-
darabine signiﬁcantly decreased IL-6 expression (Chaudhuri
et al., 2008) indicating the importance of STAT1 signalling for IL-
6 expression during viral infection. The regulation of poly I:C-in-
duced IL-6 by IFNAR1 via STAT1 still requires further elucidation.
4.3. Role of basal IFNAR1 signalling in inﬂammatory regulation in the
brain
While IL-6 showed a very much reduced expression in response
to poly I:C, it is not the only transcript signiﬁcantly lower in
IFNAR1/ than in wild types. Other inﬂammatory transcripts
including IRF7, CCL2 and IDO were signiﬁcantly less robustly
induced in IFNAR1/ mice (Fig. 6). However there were already
signiﬁcant differences between strains at the basal level. These
data suggest that basal activity of IFNAR1 (likely activated by
IFN-b, but we cannot rule out low levels of IFN-a) inﬂuences the
basal expression of CCL2, IDO and perhaps many other inﬂamma-
tory transcripts. These transcripts appear to remain responsive to
poly I:C stimulation, but never to the same levels as in WT mice,
and the origins of this lower expression may lie in the facilitating
effects of basal actions of IFN-I, not least via basal expression of
STAT1. Like IL-6, CCL2 transcription is also regulated by NFjB,
but there are studies showing that STAT1 co-regulates its induction
(Valente et al., 1998; Sikorski et al., 2014) and the current study
demonstrates that CCL2 transcripts are lower both at baseline
and post-poly I:C, congruent with the total STAT1 levels. IDO
expression is also known to be induced by IFN-I in a STAT1-depen-
dent manner (Du et al., 2000).
We also found that circulating tryptophan and kynurenine
levels were lower both basally and after poly I:C induction inIFNAR1/ mice with respect to WT controls. IDO expression was
also reduced in IFNAR1/ mice. These data suggest that IFN-I is
important in regulating the production of metabolites on this path-
way. Since KYN can cross the blood brain barrier (Fukui et al.,
1991) elevated plasma levels of KYN may also inﬂuence brain con-
centrations and indeed blocking the peripheral production of KYN,
via inhibition of liver tryptophan-2,3-dioxygenase, produces anti-
depressant effects in a repeated restraint stress model of depres-
sion (Gibney et al., 2014). It is also possible, therefore, that basal
IFN-I actions inﬂuence depressive states. We did not observe sta-
tistically signiﬁcant behavioural differences between the strains
at baseline but more comprehensive analysis of basal differences
is warranted on the basis of the observed differential basal activa-
tion/expression of inﬂammatory genes/pathways.4.4. Does diminished IL-6 explain the altered sickness behaviour
response?
There is evidence that IL-6 contributes to sickness behaviour
and thermoregulatory responses. Centrally injected IL-6 increased
body temperature and suppressed locomotor activity and food
intake in rats (Schobitz et al., 1995), although in other studies
effects of centrally administered IL-6 on locomotor activity were
not observed even at doses signiﬁcantly higher than those produc-
ing febrile and hypothalamic pituitary adrenal axis responses
(Lenczowski et al., 1999). Nonetheless, when co-administered with
IL-1b in the same study, IL-6 increases the severity of suppression
of social interaction and immobility. Consistent with a contribu-
tory rather than direct causative role, deletion of the IL-6 gene in
mice attenuates sensitivity to the depressing effects of LPS and
IL-1 on social exploration and body weight (Bluthe et al., 2000)
and using soluble gp130 (sgp130) to block IL-6 trans-signalling
also reduces LPS-induced suppression of locomotor activity
(Burton et al., 2013). We demonstrate altered thermoregulatory
and sickness behaviour responses to poly I:C in IFNAR1/. The
effects of poly I:C on burrowing appear to be mediated by IL-6, con-
sistent with reported anhedonic effects of IL-6. However, the
effects on open ﬁeld rears are independent of IL-6, although IL-6
itself further decreases rearing. IDO has also been implicated in
anhedonia emerging from sickness episodes: blocking IDO activity
can limit LPS-induced depressive-like behaviour (O’Connor et al.,
2009) and could have a role in the IFNAR1/ and IL-6-dependent
burrowing deﬁcits observed here.
Another possible mediator of the muted response of IFNAR1/
mice to poly I:C might be COX-2, which is crucial in a number of
aspects of the sickness behaviour responses including thermoregu-
latory responses (Saper et al., 2012). COX-2 is robustly induced by
systemic poly I:C (Cunningham et al., 2007) and its mRNA induc-
tion was muted in IFNAR1/ in the current study (Fig. 6). The con-
tribution of COX-2 to poly I:C-induced sickness behaviour requires
further study, although preliminary data suggests robust vascular
COX-2 expression remains in IFNAR1/ animals.5. Conclusion
This study makes it clear that the induction of type I interferons
during peripheral innate immune activation, mimicking viral infec-
tion, has effects on CNS-mediated behavioural and metabolic
changes by IL-6-dependent and independent mechanisms. Basal
activity of the type I IFN receptor affects basal STAT1 levels which
appear to alter basal expression of inﬂammatory transcripts in the
CNS and facilitates the brain’s inﬂammatory response to systemic
challenge with double stranded RNA. Since there is now evidence
that systemic poly I:C and type I IFN responses can affect progres-
sion of neurodegenerative pathology (Field et al., 2010;Wang et al.,
C. Murray et al. / Brain, Behavior, and Immunity 48 (2015) 274–286 2852004; Khorooshi et al., 2013) and cognitive decline in aging
(Baruch et al., 2014), and STAT1 is an important regulator of micro-
glial phenotype (Lawrence and Natoli, 2011) it is also pertinent to
investigate the microglial phenotype of IFNAR1/ mice in models
of microglial activation and chronic neurodegeneration.
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